Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II

Sakasai R, Teraoka H, Takagi M, Tibbetts RS (2010) Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison. J Biol Chem 285:15201–15208. doi:10.1074/jbc.M110.101808

Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53–77. doi:10.1146/annurev.pharmtox.41.1.53

Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK (2010) DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer Drug Targets 10:758–771

Oppegard LM, Ougolkov AV, Luchini DN, Schoon RA, Goodell JR, Kaur H, Billadeau DD, Ferguson DM, Hiasa H (2009) Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Eur J Pharmacol 602:223–229. doi:10.1016/j.ejphar.2008.11.044

Sciandrello G, Mauro M, Caradonna F, Catanzaro I, Saverini M, Barbata G (2010) Acrylamide catalytically inhibits topoisomerase II in V79 cells. Toxicol In Vitro 24:830–834. doi:10.1016/j.tiv.2009.12.010

Guo A, Marinaro W, Hu P, Sinko PJ (2002) Delineating the contribution of secretory transporters in the efflux of etoposide using madin-darby canine kidney (MDCK) cells overexpressing p-glycoprotein (P-gp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (CMOAT). Drug Metab Dispos 30:457–463. doi:10.1124/dmd.30.4.457

Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA (2010) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One 5:e10186. doi:10.1371/journal.pone.0010186

Lu ZQ, Fan PH, Ji M, Lou HX (2006) Terpenoids and bisbibenzyls from Chinese liverworts Conocephalum conicum and Dumortiera hirsute. J Asian Nat Prod Res 8:187–192. doi:0.1080/1028602042000325537

Cheng A, Sun L, Wu X, Lou H (2009) The inhibitory effect of a macrocyclic bisbibenzyl riccardin D on the biofilms of Candida albicans. Biol Pharm Bull 32:1417–1421. doi:10.1248/bpb.32.1417

Shi YQ, Zhu CJ, Yuan HQ, Li BQ, Gao J, Qu XJ, Sun B, Cheng YN, LiS Li X, Lou HX (2009) Marchantin C, a novel microtubule inhibitor from liverwort with anti-tumor activity both in vivo and in vitro. Cancer Lett 276:160–170. doi:10.1016/j.canlet.2008.11.004

Li X, Sun B, Zhu CJ, Yuan HQ, Shi YQ, Gao J, Li SJ, Lou HX (2009) Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Toxicol In Vitro 23:29–36. doi:10.1016/j.tiv.2008.09.015

Shi YQ, Qu XJ, Liao YX, Xie CF, Cheng YN, Li S, Lou HX (2008) Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Eur J Pharmacol 584:66–71. doi:10.1016/j.ejphar.2008.01.039

Xie CY, Zhu H, Lin LP, Miao ZH, Geng MY, Cai YJ, Chen Y, Zhao HJ, Luo HB, Zhang XW, Fan LM, ShenYM DJ (2007) MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison. Mol Cancer Ther 6:3059–3070. doi:10.1158/1535-7163.MCT-07-0014

Yang SY, Jia XZ, Feng LY, Li SY, An GS, Ni JH, Jia HT (2009) Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells. Biochem Pharmacol 77:433–443. doi:10.1016/j.bcp.2008.10.022

Okutucu B, Dincer A, Habib O, Zihnioqlu F (2007) Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 70:709–711. doi:10.1016/j.jbbm.2007.05.009

Osheroff N, Shelton ER, Brutlag DL (1983) DNA topoisomerase II from drosophila melanogaster relaxation of supercoiled DNA. J Biol Chem 258:9536–9543

Soubeyrand S, Pope L, Haché RJ (2010) Topoisomerase II alpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure. Mol Oncol 4:38–51. doi:10.1016/j.molonc.2009.09.003

Kruczynski A, Barret JM, Van Hille B, Chansard N, Astruc J, Menon Y, Duchier C, Créancier L, Hill BT (2004) Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. Clin Cancer Res 10:3156–3168. doi:10.1158/1078-0432.CCR-1305-2

Zizak Z, Juranić Z, Opsenica D, Solaja BA (2009) Mixed steroidal tetraoxanes induce apoptotic cell death in tumor cells. Invest New Drugs 27:432–439. doi:10.1007/s10637-008-9197-1

Oppegard LM, Ougolkov AV, Luchini DN, Schoon RA, Goodell JR, Kaur H, Billadeau DD, Ferguson DM, Hiasa H (2009) Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Eur J Pharmacol 602:223–229. doi:10.1016/j.ejphar.2008.11.044

Song K, Sun X, Wang J, Zhou S, Zeng H, Chen F (2008) Role of glycosylphosphatidylinositol-specific phospholipase D in the homing of umbilical cord blood, mobilized peripheral blood and bone marrow-derived hematopoietic stem/progenitor cells. Clin Exp Med 8:151–157. doi:10.1007/s10238-008-0172-0

Song T, Wu J, Fang F, Chen F, Huo L, Zhang M, Wu L, Zhai Z, Yang L, Fang J (2007) Correlation analysis between the expression of P21WAF1/CIP1, P16 proteins and human glioma. Leuk Res 31:1701–1707. doi:10.1016/j.leukres.2007.03.023

Shi LX, Ma R, Lu R, Xu Q, Zhu ZF, Wang L, Zhou CL, Li XL, Zhang HL, Yao Z (2008) Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. Cancer Lett 269:101–10. doi:10.1016/j.canlet.2008.04.033

Du Y, Lou H (2008) Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin-induced toxicity in cardiomyocytes. Eur J Pharmacol 591:96–101. doi:10.1016/j.ejphar.2008.06.068

Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, Ding J (2007) Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 6:2429–2440. doi:10.1158/1535-7163.MCT-07-0147

Hsiao CJ, Li TK, Chan YL, Hsin LW, Liao CH, Lee CH, Lyu PC, Guh JH (2008) WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Biochem Pharmacol 75:847–856. doi:10.1016/j.bcp.2007.10.012

Chen Z, Liang X, Zhang H, Xie H, Liu J, Xu Y, Zhu W, Wang Y, Wang X, Tan S, Kuang D, Qian X (2010) A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J Med Chem 53:2589–2600. doi:10.1021/jm100025u

López-Lázaro M, Willmore E, Elliott SL, Austin CA (2008) Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells. Int J Cancer 123:2217–2221. doi:10.1002/ijc.23783

Sadiq AA, Patel MR, Jacobson BA, Escobedo M, Ellis K, Oppegard LM, Hiasa H, Kratzke RA (2010) Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Invest New Drugs 28:20–25. doi:10.1007/s10637-008-9209-1

Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5:363–372

Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN (2007) BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 67:7078–7081. doi:10.1158/0008-5472.CAN-07-0601

Yao Q, Weigel B, Kersey J (2007) Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 13:1591–1600. doi:10.1158/1078-0432.CCR-06-1750

Solovyan VT, Bezvenyuk ZA, Salminen A, Austin CA, Courtney MJ (2002) The role of topoisomerase II in the excision of DNA loop domains during apoptosis. J Biol Chem 277:21458–21467. doi:10.1074/jbc.M110621200

Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BS, Robertson JD (2009) KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 76:1314–1322. doi:10.1124/mol.109.058545

Chang HY, Yang X (2000) Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 64:821–846

Fayad W, Fryknäs M, Brnjic S, Olofsson MH, Larsson R, Linder S (2009) Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. PLoS One 4:e7238. doi:10.1371/journal.pone.0007238

Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, Morjani H, Fava F, Corre E, Legrand O, Marie JP (2009) P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 9:199. doi:10.1186/1471-2407-9-199

Mantovani I, Cappellini A, Tazzari PL, Papa V, Cocco L, Martelli AM (2006) Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol 207:836–844. doi:10.1002/jcp.20628

Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM (2008) The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22:1106–1116. doi:10.1038/leu.2008.79